XLRHXNIVIZZOON-AYGNSISDSA-L

For research use only, not for therapeutic use.

  • CAT Number: I013133
  • CAS Number: 84366-81-4
  • Molecular Formula: C₂₇H₃₁N₉Na₂O₁₅P₂
  • Molecular Weight: 829.51
  • Purity: ≥95%
Inquiry Now

XLRHXNIVIZZOON-AYGNSISDSA-L (CAT: I013133) is the one-letter amino acid sequence notation for Flavin Adenine Dinucleotide (FAD) Disodium, a redox cofactor essential for numerous enzymatic reactions in metabolism. FAD is a prosthetic group that binds to specific proteins, playing a crucial role in facilitating redox reactions, electron transfer, and energy conversion processes within cells. FAD’s involvement in key metabolic pathways, such as oxidative phosphorylation and the citric acid cycle, underscores its significance in cellular energy production and the regulation of various biochemical processes.


Catalog Number I013133
CAS Number 84366-81-4
Synonyms

Flavin Adenine Dinucleotide Disodium

Molecular Formula C₂₇H₃₁N₉Na₂O₁₅P₂
Purity ≥95%
Target Others
Solubility DMSO: 6 mg/mL (Need ultrasonic and warming)
IUPAC Name disodium;[[(2R,3S,4R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] [(2R,3S,4S)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate
InChI InChI=1S/C27H33N9O15P2.2Na/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36;;/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43);;/q;2*+1/p-2/t14-,15+,16+,19-,20+,21+,26?;;/m0../s1
InChIKey XLRHXNIVIZZOON-AYGNSISDSA-L
SMILES CC1=CC2=C(C=C1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)([O-])OP(=O)([O-])OCC4C(C(C(O4)N5C=NC6=C5N=CN=C6N)O)O)O)O)O.[Na+].[Na+]
Reference

[1]. Sugiyama S, et al. Protection of chlorpromazine-induced arrhythmia by flavin-adenine-dinucleotide in canine heart. Jpn Heart J. 1979 Sep;20(5):657-65.<br>[2]. Karyakin AA, et al. Electropolymerized flavin adenine dinucleotide as an advanced NADH transducer. Anal Chem. 2004 Apr 1;76(7):2004-9.

Request a Quote